204 related articles for article (PubMed ID: 34390764)
1. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.
Yi H; Liang L; Wang H; Luo S; Hu L; Wang Y; Shen X; Xiao L; Zhang Y; Peng H; Dai C; Yuan L; Li R; Gong F; Li Z; Ye M; Liu J; Zhou H; Zhang J; Xiao X
Cancer Lett; 2021 Nov; 520():307-320. PubMed ID: 34390764
[TBL] [Abstract][Full Text] [Related]
2. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
3. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
[TBL] [Abstract][Full Text] [Related]
4. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
5. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
[TBL] [Abstract][Full Text] [Related]
6. A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
Mark C; Warrick J; Callander NS; Hematti P; Miyamoto S
Mol Cancer Res; 2022 Sep; 20(9):1456-1466. PubMed ID: 35604822
[TBL] [Abstract][Full Text] [Related]
7. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Murray MY; Zaitseva L; Auger MJ; Craig JI; MacEwan DJ; Rushworth SA; Bowles KM
Cell Cycle; 2015; 14(14):2367-75. PubMed ID: 25565020
[TBL] [Abstract][Full Text] [Related]
9. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
10. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.
Huynh M; Pak C; Markovina S; Callander NS; Chng KS; Wuerzberger-Davis SM; Bakshi DD; Kink JA; Hematti P; Hope C; Asimakopoulos F; Rui L; Miyamoto S
J Biol Chem; 2018 Feb; 293(7):2452-2465. PubMed ID: 29279332
[TBL] [Abstract][Full Text] [Related]
12. Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation.
Xie H; Gu Y; Wang W; Wang X; Ye X; Xin C; Lu M; Reddy BA; Shu P
Sci Rep; 2020 Jan; 10(1):766. PubMed ID: 31964975
[TBL] [Abstract][Full Text] [Related]
13. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
14. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.
Liang L; He Y; Wang H; Zhou H; Xiao L; Ye M; Kuang Y; Luo S; Zuo Y; Feng P; Yang C; Cao W; Liu T; Roy M; Xiao X; Liu J
Br J Haematol; 2020 Oct; 191(1):62-76. PubMed ID: 32314355
[TBL] [Abstract][Full Text] [Related]
15. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Chauhan D; Li G; Podar K; Hideshima T; Shringarpure R; Catley L; Mitsiades C; Munshi N; Tai YT; Suh N; Gribble GW; Honda T; Schlossman R; Richardson P; Sporn MB; Anderson KC
Blood; 2004 Apr; 103(8):3158-66. PubMed ID: 15070698
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation.
Bariana M; Cassella E; Rateshwar J; Ouk S; Liou HC; Heller C; Colorado I; Feinman R; Makhdoom A; Siegel DS; Heller G; Tuckett A; Mondello P; Zakrzewski JL
Mol Cancer Ther; 2022 Dec; 21(12):1798-1809. PubMed ID: 36190955
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram/copper targets stem cell-like ALDH
Jin N; Zhu X; Cheng F; Zhang L
J Cell Biochem; 2018 Aug; 119(8):6882-6893. PubMed ID: 29665144
[TBL] [Abstract][Full Text] [Related]
18. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C
Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939
[TBL] [Abstract][Full Text] [Related]
19. KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway.
Song IS; Jeong YJ; Nyamaa B; Jeong SH; Kim HK; Kim N; Ko KS; Rhee BD; Han J
BMB Rep; 2015 Oct; 48(10):571-6. PubMed ID: 25772758
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]